ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Repare Therapeutics Inc. | RPTX | United States of America | $114.24M | 447 |
| ProMIS Neurosciences Inc. Delisted | PMN | Canada | $127.79M | 379 |
| Nykode Therapeutics ASA | NYKD | Norway | $110.95M | 565 |
| Helix BioPharma Corp. | HBP | Canada | $79.85M | 574 |
| Cardiff Oncology, Inc. | CRDF | United States of America | $86.83M | 1,149 |
| SynAct Pharma | SYNACT | Sweden | $79.46M | 284 |
| GENELUX Corp | GNLX | United States of America | $103.05M | 360 |
| Aldeyra Therapeutics, Inc. | ALDX | United States of America | $101.11M | 695 |
| BRIM Biotechnology, Inc. | 6885 | Taiwan | $87.61M | 483 |
| Adocia | ADOC | France | $98.99M | 932 |
| Dogwood Therapeutics, Inc. | DWTX | United States of America | $98.17M | 340 |
| Adverum Biotechnologies, Inc. Delisted | ADVM | United States of America | $96.26M | 982 |
| Biomea Fusion, Inc. | BMEA | United States of America | $95.44M | 318 |
| COGNITION THERAPEUTICS INC | CGTX | United States of America | $100.72M | 320 |
| Coya Therapeutics, Inc. | COYA | United States of America | $108.84M | 244 |
| Q32 Bio Inc. | QTTB | United States of America | $93.92M | 590 |
| Pyxis Oncology, Inc. | PYXS | United States of America | $92.36M | 367 |
| TuHURA Biosciences, Inc. | HURA | United States of America | $152.20M | 924 |
| Cantargia | CANTA | Sweden | $91.92M | 637 |
| ImageneBio, Inc. | IMA | United States of America | $91.69M | 329 |
| AB Science | AB | France | $47.81M | 803 |
| Anixa Biosciences Inc | ANIX | United States of America | $100.71M | 995 |
| Aardvark Therapeutics, Inc. | AARD | United States of America | $83.12M | 121 |
| ONCOLYTICS BIOTECH INC | ONCY | United States of America | $86.62M | 1,219 |
| Cinclus Pharma Holding AB | CINPHA | Sweden | $60.26M | 103 |
| SPRUCE BIOSCIENCES, INC. | SPRB | United States of America | $119.83M | 377 |
| OSE Immunotherapeutics | OSE | France | $93.05M | 874 |
| Vivani Medical, Inc. | VANI | United States of America | $97.45M | 847 |
| KAZIA THERAPEUTICS LTD | KZIA | United States of America | $154.95M | 2,476 |
| Rani Therapeutics Holdings, Inc. | RANI | United States of America | $103.80M | 394 |
| Lytix Biopharma AS | LYTIX | Norway | $77.18M | 350 |
| PolyPid Ltd. | PYPD | Israel | $83.58M | 284 |
| BeyondSpring Inc. | BYSI | United States of America | $83.08M | 277 |
| OKYO Pharma Ltd | OKYO | United States of America | $81.87M | 328 |
| Gossamer Bio, Inc. | GOSS | United States of America | $41.07M | 519 |
| HEMOGENYX PHARMACEUTICALS PLC | HEMO | United Kingdom | $69.36M | 481 |
| FARON PHARMACEUTICALS OY | FARN | Finland | $80.63M | 709 |
| SUTRO BIOPHARMA, INC. | STRO | United States of America | $79.09M | 658 |
| Gain Therapeutics, Inc. | GANX | United States of America | $76.78M | 242 |
| aTYR PHARMA INC | ATYR | United States of America | $63.06M | 772 |
| Abliva Delisted | ABLI | Sweden | $76.59M | 647 |
| MAIA Biotechnology, Inc. | MAIA | United States of America | $79.04M | 506 |
| PLIANT THERAPEUTICS, INC. | PLRX | United States of America | $72.75M | 472 |
| FRACTYL HEALTH, INC. | GUTS | United States of America | $107.66M | 255 |
| XBiotech Inc. | XBIT | United States of America | $72.10M | 403 |
| Grace Therapeutics, Inc. | GRCE | Canada | $71.64M | 598 |
| ALTERITY THERAPEUTICS LIMITED | ATH | Australia | $87.37M | 2,491 |
| iBio, Inc. | IBIO | United States of America | $70.12M | 815 |
| PMV Pharmaceuticals, Inc. | PMVP | United States of America | $66.13M | 396 |
| Cingulate Inc. | CING | United States of America | $66.81M | 486 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.